ID   ZR75B Ad120
AC   CVCL_ZZ26
DR   cancercelllines; CVCL_ZZ26
DR   Wikidata; Q102115155
RX   PubMed=8562478;
RX   PubMed=9815641;
CC   Population: Caucasian.
CC   Doubling time: 47.8 hours (PubMed=8562478; PubMed=9815641).
CC   Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; HGNC:5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5614 ! ZR-75-B
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 19-12-24; Version: 8
//
RX   PubMed=9815641;
RA   Wosikowski, Katja
RA   Schuurhuis, Danita H.
RA   Kops, Geert J.P.L.
RA   Saceda, Miguel
RA   Bates, Susan E.
RT   "Altered gene expression in drug-resistant human breast cancer
RT   cells.";
RL   Clin. Cancer Res. 3:2405-2414(1997).
//
RX   PubMed=8562478;
RA   Wosikowski, Katja
RA   Regis, Joanna T.
RA   Robey, Robert W.
RA   Alvarez, Manuel
RA   Buters, Jeroen Titus Maria
RA   Gudas, Jean Marie
RA   Bates, Susan E.
RT   "Normal p53 status and function despite the development of drug
RT   resistance in human breast cancer cells.";
RL   Cell Growth Differ. 6:1395-1403(1995).
//